Sarat Chandarlapaty (S Chandarlapaty)

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 53

Top Topics

Positive Breast Cancer

Gene Expression

Estrogen Receptor

Endoplasmic Reticulum

Top Venues

NPJ breast cancer

Nature reviews. Clinical oncology

Nature communications

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Nicholas Mai, Jie-Fu Chen, Satshil Rana, Mark Robson, Sarat Chandarlapaty, Ezra Y Rosen
Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer. NPJ precision oncology 8 (1) (2024)
Nicholas Mai, Jie-Fu Chen, Satshil Rana, Mark Robson, Sarat Chandarlapaty, Ezra Y Rosen
Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer. NPJ precision oncology 8 (1) (2024)
Antonio Marra, Sarat Chandarlapaty, Shanu Modi
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Nature reviews. Clinical oncology 21 (3) (2024)
Nicholas Mai, Jie-Fu Chen, Satshil Rana, Mark Robson, Sarat Chandarlapaty, Ezra Y Rosen
Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer. NPJ precision oncology 8 (1) (2024)
Antonio Marra, Sarat Chandarlapaty, Shanu Modi
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Nature reviews. Clinical oncology 21 (3) (2024)
Antonio Marra, Sarat Chandarlapaty, Shanu Modi
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Nature reviews. Clinical oncology (2024)
Anton Safonov, Antonio Marra, Chaitanya Bandlamudi, Ben O'Leary, Bradley Wubbenhorst, Emanuela Ferraro, Enrico Moiso, Minna Lee, Julia An, Mark T A Donoghue, Marie Will, Fresia Pareja, Emily Nizialek, Natalia Lukashchuk, Eleni Sofianopoulou, Yuan Liu, Xin Huang, Mehnaj Ahmed, Miika M Mehine, Dara Ross, Diana Mandelker, Marc Ladanyi, Nikolaus Schultz, Michael F Berger, Maurizio Scaltriti, Jorge S Reis-Filho, Bob T Li, Ken Offit, Larry Norton, Ronglai Shen, Sohrab Shah, Kara N Maxwell, Fergus Couch, Susan M Domchek, David B Solit, Katherine L Nathanson, Mark E Robson, Nicholas C Turner, Sarat Chandarlapaty, Pedram Razavi
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer. bioRxiv : the preprint server for biology (2024)
Fresia Pareja, Higinio Dopeso, Yi Kan Wang, Andrea M Gazzo, David N Brown, Monami Banerjee, Pier Selenica, Jan H Bernhard, Fatemeh Derakhshan, Edaise M Da Silva, Lorraine Colon Cartagena, Thais Basili de Oliveira, Antonio Marra, Jillian Sue, Qiqi Ye, Arnaud Da Cruz Paula, Selma Yeni Yildirim, Isaac X Pei, Anton Safonov, Hunter Green, Kaitlyn Y Gill, Yingjie Zhu, Matthew C H Lee, Ran A Godrich, Adam Casson, Jorge S Reis-Filho, Nadeem Riaz, Hannah Y Wen, Edi Brogi, Diana L Mandelker, Matthew G Hanna, Jeremy D Kunz, Brandon Rothrock, Sarat Chandarlapaty, Christopher Kanan, Joe Oakley, David S Klimstra, Thomas J Fuchs, Jorge Sergio Reis-Filho
A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms. Cancer research (2024)
Jacob A Boyer, Malvika Sharma, Madeline A Dorso, Nicholas Mai, Corina Amor, Jason M Reiter, Ram Kannan, Sunyana Gadal, Jianing Xu, Matthew Miele, Zhuoning Li, Xiaoping Chen, Qing Chang, Fresia Pareja, Stephan Worland, Douglas Warner, Sam Sperry, Gary G Chiang, Peggy A Thompson, Guangli Yang, Ouathek Ouerfelli, Elisa de Stanchina, Hans-Guido Wendel, Ezra Y Rosen, Sarat Chandarlapaty, Neal Rosen
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer. bioRxiv : the preprint server for biology (2024)
Nicholas Mai, Carlos H Dos Anjos, Pedram Razavi, Anton Safonov, Sujata Patil, Yuan Chen, Joshua Z Drago, Shanu Modi, Jacqueline F Bromberg, Chau T Dang, Dazhi Liu, Larry Norton, Mark E Robson, Sarat Chandarlapaty, Komal L Jhaveri
Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast Cancer. Research square (2024)
Antonio Marra, Sarat Chandarlapaty, Shanu Modi
Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Nature reviews. Clinical oncology (2024)
Antonio Marra, Sarat Chandarlapaty, Shanu Modi
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Nature reviews. Clinical oncology 21 (3) (2024)
Komal L Jhaveri, Nicholas Mai, Carlos Henrique Dos Anjos, Pedram Razavi, Anton Safonov, Sujata Patil, Yuan Chen, Joshua Drago, Shanu Modi, Jacqueline Bromberg, Chau T Dang, Dazhi Liu, Larry Norton, Mark E Robson, Sarat Chandarlapaty
Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast Cancer. Research square (2024)
Jacob A Boyer, Malvika Sharma, Madeline A Dorso, Nicholas Mai, Corina Amor, Jason M Reiter, Ram Kannan, Sunyana Gadal, Jianing Xu, Matthew Miele, Zhuoning Li, Xiaoping Chen, Qing Chang, Fresia Pareja, Stephan Worland, Douglas Warner, Sam Sperry, Gary G Chiang, Peggy A Thompson, Guangli Yang, Ouathek Ouerfelli, Elisa de Stanchina, Hans-Guido Wendel, Ezra Y Rosen, Sarat Chandarlapaty, Neal Rosen
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer. bioRxiv : the preprint server for biology (2024)
Belinda Kingston, Alex Pearson, Maria Teresa Herrera-Abreu, Li-Xuan Sim, Rosalind J Cutts, Heena Shah, Laura Moretti, Lucy Suzanne Kilburn, Hannah Johnson, Iain R J Macpherson, Alistair Ring, Judith M Bliss, Yingwei Hou, Weiyi Toy, John A Katzenellenbogen, Sarat Chandarlapaty, Nicholas C Turner
ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer discovery (2023)
Marie Will, Jackson Liang, Ciara Metcalfe, Sarat Chandarlapaty
Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nature reviews. Cancer (2023)
Avantika Gupta, Joshua Z Drago, Sarat Chandarlapaty
ADCs or: How I Learned to Stop Worrying and Love Chemotherapy. Cancer discovery 13 (4) (2023)
Madeline A Dorso, Payal T Patel, Aleksandr Pankov, Jacob A Boyer, Rajesh Kumar Soni, Isabella S Del Priore, Omar Hayatt, Amanda Kulick, Connor J Hagen, Elisa De Stanchina, Melissa R Junttila, Anneleen Daemen, Lori S Friedman, Ronald C Hendrickson, Sarat Chandarlapaty
A Druggable FOXA1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung Cancer. Cancer research communications 3 (9) (2023)
Sarat Chandarlapaty, Maura N Dickler, José Alejandro Pérez-Fidalgo, Rafael Villanueva-Vázquez, Jennifer M Giltnane, Mary R Gates, Ching-Wei Chang, Sravanthi Cheeti, Jill Fredrickson, Xiaojing Wang, Ann Collier, Heather M Moore, Ciara Metcalfe, Jennifer Lauchle, Eric W Humke, Aditya Bardia
An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Nelson S Moss, Jolene M Singh, Anne S Reiner, Joshua Z Drago, Shanu Modi, Andrew D Seidman, Sarat Chandarlapaty, Dara S Ross
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis. NPJ breast cancer 9 (1) (2023)
Emanuela Ferraro, Jasmeet Singh, Sujata Patil, Pedram Razavi, Shanu Modi, Sarat Chandarlapaty, Andrea V Barrio, Rachna Malani, Ingo K Mellinghoff, Adrienne A Boire, Hannah Y Wen, Edi Brogi, Andrew D Seidman, Larry Norton, Mark E Robson, Chau T Dang
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. NPJ breast cancer 8 (1) (2022)
Naren Ramakrishna, Carey K Anders, Nancy U Lin, Aki Morikawa, Sarah Temin, Sarat Chandarlapaty, Jennie R Crews, Nancy E Davidson, Maria Alice B Franzoi, Jeffrey J Kirshner, Ian E Krop, Debra A Patt, Jane Perlmutter, Sharon H Giordano
Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (23) (2022)
Amish J Patel, Sarah Warda, Jesper L V Maag, Rohan Misra, Miguel A Miranda-Román, Mohini R Pachai, Cindy J Lee, Dan Li, Naitao Wang, Gabriella Bayshtok, Eve Fishinevich, Yinuo Meng, Elissa W P Wong, Juan Yan, Emily Giff, Melissa B Pappalardi, Michael T McCabe, Jonathan A Fletcher, Charles M Rudin, Sarat Chandarlapaty, Joseph Michael Scandura, Richard P Koche, Jacob Lowell Glass, Cristina R Antonescu, Deyou Zheng, Juliet Chen, Ping Chi
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. Cancer discovery 12 (9) (2022)
Erik Ladewig, Flavia Michelini, Komal Jhaveri, Hatice Ulku Osmanbeyoglu, Javier Carmona, Lauren Fairchild, Adler G Zuniga, Amaia Arruabarrena-Aristorena, Emiliano Cocco, Ryan Blawski, Srushti Kittane, Yuhan Zhang, Mirna Sallaku, Laura Baldino, Vasilis Hristidis, Sarat Chandarlapaty, Omar Abdel-Wahab, Christina S Leslie, Maurizio Scaltriti, Eneda Toska
The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation. Cancer research 82 (12) (2022)
Sharon H Giordano, Maria Alice B Franzoi, Sarah Temin, Carey K Anders, Sarat Chandarlapaty, Jennie R Crews, Jeffrey J Kirshner, Ian E Krop, Nancy U Lin, Aki Morikawa, Debra A Patt, Jane Perlmutter, Naren Ramakrishna, Nancy E Davidson
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (23) (2022)
Antonio Strillacci, Pasquale Sansone, Vinagolu K Rajasekhar, Mesruh Turkekul, Vitaly Boyko, Fanli Meng, Brian R Loomis, David Brown, Michael F Berger, Ronald C Hendrickson, Qing Chang, Elisa de Stanchina, Fresia Pareja, Jorge Sergio Reis-Filho, Ramya Segu Rajappachetty, Isabella Del Priore, Bo Liu, Yanyan Cai, Alex Penson, Chiara Mastroleo, Marjan Berishaj, Francesca Borsetti, Enzo Spisni, David C Lyden, Sarat Chandarlapaty, Jacqueline F Bromberg
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance. NPJ breast cancer 8 (1) (2022)
Aditya Bardia, Sarat Chandarlapaty, Hannah M Linden, Gary A Ulaner, Alice Gosselin, Sylvaine Cartot-Cotton, Patrick Cohen, Séverine Doroumian, Gautier Paux, Marina Celanovic, Vasiliki Pelekanou, Jeffrey E Ming, Nils Ternès, Monsif Bouaboula, Joon Sang Lee, Anne-Laure Bauchet, Mario Campone
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. Nature communications 13 (1) (2022)
Angela Rose Brannon, Gowtham Jayakumaran, Monica Diosdado, Juber Patel, Anna Razumova, Yu Hu, Fanli Meng, Mohammad Haque, Justyna Sadowska, Brian J Murphy, Tessara Baldi, Ian Johnson, Ryan Ptashkin, Maysun M Hasan, Preethi Srinivasan, Anoop Balakrishnan Rema, Ivelise Rijo, Aaron Agarunov, Helen Won, Dilmi Perera, David N Brown, Aliaksandra Samoila, Xiaohong Jing, Erika Gedvilaite, Julie L Yang, Dennis P Stephens, Jenna-Marie Dix, Nicole DeGroat, Khedoudja Nafa, Aijazuddin Syed, Alan Li, Emily S Lebow, Anita S Bowman, Donna C Ferguson, Ying Liu, Douglas A Mata, Rohit Sharma, Soo-Ryum Yang, Tejus Bale, Jamal K Benhamida, Jason C Chang, Snjezana Dogan, Meera R Hameed, Jaclyn F Hechtman, Christine Moung, Dara S Ross, Efsevia Vakiani, Chad M Vanderbilt, JinJuan Yao, Pedram Razavi, Lillian M Smyth, Sarat Chandarlapaty, Gopakumar V Iyer, Wassim Abida, James J Harding, Benjamin Krantz, Eileen M O'Reilly, Helena A Yu, Bob T Li, Charles M Rudin, Luis A Diaz, David B Solit, Maria E Arcila, Marc Ladanyi, Brian R Loomis, Dana Tsui, Michael F Berger, Ahmet Zehir, Ryma Benayed
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature communications 12 (1) (2021)
Joshua Z Drago, Shanu Modi, Sarat Chandarlapaty
Unlocking the potential of antibody-drug conjugates for cancer therapy. Nature reviews. Clinical oncology 18 (6) (2021)
Edaise M Da Silva, Pier Selenica, Mahsa Vahdatinia, Fresia Pareja, Arnaud Da Cruz Paula, Lorenzo Ferrando, Andrea M Gazzo, Higinio Dopeso, Dara S Ross, Ariya Bakhteri, Nadeem Riaz, Sarat Chandarlapaty, Pedram Razavi, Larry Norton, Hannah Y Wen, Edi Brogi, Jorge S Reis-Filho, Hong Zhang, Jorge Sergio Reis-Filho
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. NPJ breast cancer 7 (1) (2021)
Lillian M Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Komal Jhaveri, Andrea Varga, Andrea Wong, Alison M Schram, Helen Ambrose, T Hedley Carr, Elza C de Bruin, Carolina Salinas-Souza, Andrew Foxley, Joana Hauser, Justin P O Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Myria Nikolaou, Gaia Schiavon, Pedram Razavi, Udai Banerji, José Baselga, David M Hyman, Sarat Chandarlapaty
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. NPJ breast cancer 7 (1) (2021)
Donna C Ferguson, Douglas A Mata, Timothy Ky Tay, Tiffany A Traina, Ayca Gucalp, Sarat Chandarlapaty, Timothy M D' Alfonso, Edi Brogi, Kerry Mullaney, Marc Ladanyi, Maria E Arcila, Ryma Benayed, Dara S Ross
Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (2021)
Alison E Smith, Emanuela Ferraro, Anton Safonov, Cristina Bernado Morales, Enrique J Arenas Lahuerta, Qing Li, Amanda Kulick, Dara Ross, David B Solit, Elisa de Stanchina, Jorge Sergio Reis-Filho, Neal X Rosen, Joaquín Arribas, Pedram Razavi, Sarat Chandarlapaty
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nature communications 12 (1) (2021)
Komal Jhaveri, Joshua Z Drago, Payal Deepak Shah, Rui Wang, Fresia Pareja, Fanni Ratzon, Alexia Iasonos, Sujata Patil, Neal X Rosen, Monica N Fornier, Nancy T Sklarin, Sarat Chandarlapaty, Shanu Modi
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (14) (2021)
Christopher G Mayne, Weiyi Toy, Kathryn E Carlson, Trusha Bhatt, Sean W Fanning, Geoffrey L Greene, Benita S Katzenellenbogen, Sarat Chandarlapaty, John A Katzenellenbogen, Emad Tajkhorshid
Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer. Molecular cancer research : MCR 19 (9) (2021)
Yanyan Cai, Guotai Xu, Fan Wu, Flavia Michelini, Carmen Chan, Xuan Qu, Pier Selenica, Erik Ladewig, Hatice Ulku Osmanbeyoglu, Yuanming Cheng, Alison Zhao, Komal Jhaveri, Eneda Toska, Marta Jimenez, Alexandra Jacquet, Alicia Tran-Dien, Fabrice Andre, Sarat Chandarlapaty, Jorge S Reis-Filho, Pedram Razavi, Maurizio Scaltriti
Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors. Cancer research 81 (9) (2021)
Qing Li, Baishan Jiang, Jiaye Guo, Hong Shao, Isabella S Del Priore, Qing Chang, Rei Kudo, Zhiqiang Li, Pedram Razavi, Bo Liu, Andrew S Boghossian, Matthew G Rees, Melissa A Ronan, Jennifer A Roth, Katherine Aleisha Donovan, Marta Palafox, Jorge S Reis-Filho, Elisa de Stanchina, Eric S Fischer, Neal X Rosen, Violeta Serra, Andrew Koff, John D Chodera, Nathanael S Gray, Sarat Chandarlapaty
INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors. Cancer discovery (2021)
Lillian M Smyth, Kenji Tamura, Mafalda Oliveira, Eva Ciruelos Gil, Ingrid A Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen J Ambrose, Jack Ashton, Alan Barnicle, Des D Cashell, Claire Corcoran, Elza C de Bruin, Andrew Foxley, Joana Hauser, Justin P O Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udai Banerji, Maurizio Scaltriti, Barry S Taylor, Sarat Chandarlapaty, José Baselga, David M Hyman
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (15) (2020)
Kimberly Dessources, Arnaud Da Cruz Paula, Fresia Pareja, Anthe Stylianou, Paulina Cybulska, Amir Farmanbar, Sarat Chandarlapaty, Nadeem R Abu-Rustum, Jorge Sergio Reis-Filho, Jorge S Reis-Filho, Jennifer J Mueller
Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. JCO precision oncology 4 (2020)
Neil Vasan, Pedram Razavi, Jared L Johnson, Hong Shao, Hardik Shah, Alesia Antoine, Erik Ladewig, Alexander N Gorelick, Ting-Yu Lin, Eneda Toska, Guotai Xu, Abiha Kazmi, Matthew T Chang, Barry S Taylor, Maura N Dickler, Komal Jhaveri, Sarat Chandarlapaty, Raúl Rabadán, Ed Reznik, Melissa Laird Smith, Robert Sebra, Frauke Schimmoller, Timothy R Wilson, Lori S Friedman, Lewis C Cantley, Maurizio Scaltriti, Jose Baselga
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science (New York, N.Y.) 366 (6466) (2020)
Fresia Pareja, Lorenzo Ferrando, Simon S K Lee, Francisco Beca, Pier Selenica, David N Brown, Amir Farmanbar, Arnaud Da Cruz Paula, Mahsa Vahdatinia, Hong Zhang, Gabriele Zoppoli, Hannah Y Wen, Edi Brogi, Mark E Robson, Pedram Razavi, Sarat Chandarlapaty, Jorge S Reis-Filho, Jorge Sergio Reis-Filho
The genomic landscape of metastatic histologic special types of invasive breast cancer. NPJ breast cancer 6 (2020)
Sizhi Paul Gao, Amber J Kiliti, Kai Zhang, Naresh Vasani, Ninghui Mao, Emmet Jordan, Hannah C Johnsen, Tripti Shrestha Bhattarai, Wenhuo Hu, Madeline Dorso, James A Rodrigues, Kwanghee Kim, Aphrothiti J Hanrahan, Pedram Razavi, Brett Carver, Sarat Chandarlapaty, Jorge S Reis-Filho, Barry S Taylor, David B Solit
AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling. Molecular cancer research : MCR 19 (4) (2020)
Lillian M Smyth, Sarina A Piha-Paul, Helen H Won, Alison M Schram, Cristina Saura, Sherene Loi, Janice Lu, Geoffrey I Shapiro, Dejan Juric, Ingrid A Mayer, Carlos L Arteaga, Macarena I de la Fuente, Adam M Brufksy, Iben Spanggaard, Morten Mau Sorensen, Monica Arnedos, Victor Moreno, Valentina Boni, Joohyuk Sohn, Lee S Schwartzberg, Xavier Gonzalez, Andres Cervantes, François-Clement Bidard, Alexander N Gorelick, Richard B Lanman, Rebecca J Nagy, Gary A Ulaner, Sarat Chandarlapaty, Komal Jhaveri, Elena I Gavrila, Catherine Zimel, S Duygu Selcuklu, Myra Melcer, Aliaksandra Samoila, Yanyan Cai, Maurizio Scaltriti, Grace Mann, Feng Xu, Lisa D Eli, Melanie Dujka, Alshad S Lalani, Richard Bryce, José Baselga, Barry S Taylor, David B Solit, Funda Meric-Bernstam, David M Hyman
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer discovery 10 (2) (2019)
Ryan J O Dowling, Joseph A Sparano, Pamela J Goodwin, Francois-Clement Bidard, David W Cescon, Sarat Chandarlapaty, Joseph O Deasy, Mitch Dowsett, Robert C Gray, Norah L Henry, Funda Meric-Bernstam, Jane Perlmutter, George W Sledge, Mangesh A Thorat, Scott V Bratman, Lisa Anne Carey, Martin C Chang, Angela DeMichele, Marguerite Ennis, Katarzyna J Jerzak, Larissa A Korde, Ana Elisa Lohmann, Eleftherios P Mamounas, Wendy R Parulekar, Meredith M Regan, Daniel Schramek, Vuk Stambolic, Timothy J Whelan, Antonio C Wolff, James R Woodgett, Kevin Kalinsky, Daniel F Hayes
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI cancer spectrum 3 (4) (2019)
Ryan J O Dowling, Kevin Kalinsky, Daniel F Hayes, Francois-Clement Bidard, David W Cescon, Sarat Chandarlapaty, Joseph O Deasy, Mitch Dowsett, Robert C Gray, Norah L Henry, Funda Meric-Bernstam, Jane Perlmutter, George W Sledge, Scott V Bratman, Lisa Anne Carey, Martin C Chang, Angela DeMichele, Marguerite Ennis, Katarzyna J Jerzak, Larissa A Korde, Ana Elisa Lohmann, Eleftherios P Mamounas, Wendy R Parulekar, Meredith M Regan, Daniel Schramek, Vuk Stambolic, Mangesh A Thorat, Timothy J Whelan, Antonio C Wolff, James R Woodgett, Joseph A Sparano, Pamela J Goodwin
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI cancer spectrum 3 (4) (2019)
John A Katzenellenbogen, Christopher G Mayne, Benita S Katzenellenbogen, Geoffrey L Greene, Sarat Chandarlapaty
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nature reviews. Cancer 18 (6) (2019)
Qingfei Zheng, Nathaniel D Omans, Rachel Leicher, Adewola Osunsade, Albert S Agustinus, Efrat Finkin-Groner, Hannah D'Ambrosio, Bo Liu, Sarat Chandarlapaty, Shixin Liu, Yael David
Reversible histone glycation is associated with disease-related changes in chromatin architecture. Nature communications 10 (1) (2019)
Sean W Fanning, Rinath Jeselsohn, Venkatasubramanian Dharmarajan, Christopher G Mayne, Mostafa Karimi, Gilles Buchwalter, René Houtman, Weiyi Toy, Colin E Fowler, Ross Han, Muriel Lainé, Kathryn E Carlson, Teresa A Martin, Jason Nowak, Jerome C Nwachukwu, David J Hosfield, Sarat Chandarlapaty, Emad Tajkhorshid, Kendall W Nettles, Patrick R Griffin, Yang Shen, John A Katzenellenbogen, Myles A Brown, Geoffrey L Greene
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. eLife 7 (2018)
Felipe C Geyer, Anqi Li, Anastasios D Papanastasiou, Alison Smith, Pier Selenica, Kathleen A Burke, Marcia Edelweiss, Huei-Chi Wen, Salvatore Piscuoglio, Anne M Schultheis, Luciano G Martelotto, Fresia Pareja, Rahul Kumar, Alissa Brandes, Dan Fan, Thais Basili, Arnaud Da Cruz Paula, John R Lozada, Pedro Blecua, Simone Muenst, Achim A Jungbluth, Maria P Foschini, Hannah Y Wen, Edi Brogi, Juan Palazzo, Brian P Rubin, Charlotte C K Ng, Larry Norton, Zsuzsanna Varga, Ian O Ellis, Emad A Rakha, Sarat Chandarlapaty, Britta Weigelt, Jorge S Reis-Filho
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nature communications 9 (1) (2018)
Jennifer M Giltnane, Katherine E Hutchinson, Thomas P Stricker, Luigi Formisano, Christian D Young, M Valeria Estrada, Mellissa J Nixon, Liping Du, Violeta Sanchez, Paula I Gonzalez Ericsson, Maria G Kuba, Melinda E Sanders, Xinmeng Jasmine Mu, Eliezer Van Allen, Nikhil Wagle, Ingrid A Mayer, Vandana Abramson, Henry Gόmez, Monica Rizzo, Weiyi Toy, Sarat Chandarlapaty, Erica L Mayer, Jason Christiansen, Danielle A Murphy, Kerry Fitzgerald, Kai Wang, Jeffery S Ross, Vincent A Miller, Phillip J Stephens, Roman Yelensky, Levi Garraway, Yu Shyr, Ingrid Meszoely, Justin M Balko, Carlos L Arteaga
Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science translational medicine 9 (402) (2018)
Emiliano Cocco, F Javier Carmona, Pedram Razavi, Helen H Won, Yanyan Cai, Valentina Rossi, Carmen Chan, James Cownie, Joanne Soong, Eneda Toska, Sophie G Shifman, Ivana Sarotto, Peter Savas, Michael J Wick, Kyriakos P Papadopoulos, Alyssa Moriarty, Richard E Cutler, Francesca Avogadri-Connors, Alshad S Lalani, Richard P Bryce, Sarat Chandarlapaty, David M Hyman, David B Solit, Valentina Boni, Sherene Loi, Jose Baselga, Michael F Berger, Filippo Montemurro, Maurizio Scaltriti
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science signaling 11 (551) (2018)
Kinisha Gala, Qing Li, Amit Sinha, Pedram Razavi, Madeline Dorso, Francisco Sanchez-Vega, Young Rock Chung, Ronald Hendrickson, James J Hsieh, Michael Berger, Nikolaus Schultz, Alessandro Pastore, Omar Abdel-Wahab, Sarat Chandarlapaty
KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function. Oncogene 37 (34) (2018)
C Yang, Z Li, T Bhatt, M Dickler, D Giri, M Scaltriti, J Baselga, N Rosen, Sarat Chandarlapaty
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene 36 (16) (2016)